Adults 18 years of age or older with a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months, may qualify to participate. Individuals must have plaque psoriasis covering 2% or more of their body, with mild to moderate disease at the time of study entry.
Eligible participants will receive investigational oral medication (active drug or placebo). Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last about 32 weeks and include about 12 visits to the study centre.
Email Tina Craig, Clinical Research Coordinator at DermEffects to register.